Drug Profile
TAS 266
Alternative Names: TAS-266Latest Information Update: 22 Jun 2018
Price :
$50
*
At a glance
- Originator Ablynx; Novartis
- Developer Novartis
- Class Antineoplastics
- Mechanism of Action TRAIL receptor 2 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 19 Jun 2018 Ablynx has been acquired by Sanofi
- 31 Dec 2012 Discontinued - Phase-I for Solid tumours in USA (IV)
- 30 Sep 2012 Novartis terminates phase I trial in Solid tumours in the USA (NCT01529307)